TransCode Therapeutics, Inc. RNAZ
1.37 USD -0.17 (-11.04%)
Nov 10, 2026, 1:27 PM EST
1.38 Day range 1.55
1.38 52-week range 12.60
- YTD
- -79.94%
- 1 year
- -85.43%
News
benzinga.com TransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138 TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and
benzinga.com Natera, TransCode Therapeutics Partnering To Support Enrollment For TransCode’s Phase 2a Study Of TTX-MC138 In Participants With Colorectal Cancer Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based…- benzinga.com TransCode Therapeutics Announces Updated Clinical Data From Phase 1a Clinical Trial Of TTX-MC138, Reinforcing Evidence Of Antitumor Activity In Heavily Pretreated Patients With Advanced Solid Tumors Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumorsIn the 14 efficacy-evaluable patients:71.4% stable disease rate57.1% of…
benzinga.com TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced significant advancements…- benzinga.com TransCode Therapeutics CFO Tom Fitzgerald Plans To Retire; John Tattory To Serve As Interim Finance Chief, Effective Immediately TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market session. The market value of their outstanding shares is at $1.6 million. Modular Medical (NASDAQ:MODD)…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million. Quanterix (NASDAQ:QTRX) shares…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market session. Onconetix (NASDAQ:ONCO) shares moved upwards by 27.46% to $0.96. The company's market cap stands at…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's regular session. The market value of their outstanding shares is at $4.8 million. Seer (NASDAQ:SEER)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com TransCode Therapeutics Q1 EPS $(21.28) Up From $(70.16) YoY TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.67 percent increase over losses of $(70.16) per share from the same period last year.
benzinga.com Transcode Therapeutics Files Prospecuts For Resale Of Up To 15,955,543 Shares By Selling Stockholders TransCode Therapeutics, Inc.15,955,543 SharesCommon StockThis prospectus relates to the possible resale or other disposition from time to time by the selling stockholders named in this prospectus of…
benzinga.com TransCode Therapeutics Enters Into Agreement With Institutional Healthcare Investor For Financing Of Up To $20M TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it…- benzinga.com TransCode Therapeutics Enters Into Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement With Unleash Immuno Oncolytics TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Transcode Therapeutics In Collaboration With Quantum Leap Healthcare Collaborative, Submitted An FDA Investigational New Drug Application Amendment For Planned Phase 2A Trial With Transcode's TTX-MC138 As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com TransCode Achieves Phase 1a Safety Milestone For TTX-MC138, Advancing To Phase 2a After Durability And Disease Control In Cancer Patients Safety primary endpoint achievedMedian treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trialRECIST data with apparent stable disease lasting over 4 months…
benzinga.com TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout TransCode Therapeutics Inc. (NASDAQ: RNAZ) to acquire Polynoma LLC and receive $25 million investment from CK Life Sciences.- benzinga.com TransCode Therapeutics Signs Agreement To Acquire Polynoma For $20M Cash, $5M Promissory Note BOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Reported May 14, 2025: TransCode Therapeutics Q1 EPS $(2.51) Misses $(2.00) Estimate TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(2.00) by 25.5 percent. This is a 88.24 percent increase over…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Futures of benchmark indices were lower in premarket.
benzinga.com Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket 
benzinga.com Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com TransCode Therapeutics Announces 1-For-28 Reverse Stock Split; The Effective Date Of The Reverse Stock Split Has Not Yet Been Determined Split designed to achieve compliance with Nasdaq minimum bid price requirementsBOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug TransCode Therapeutics advances Phase 1a trial of TTX-MC138 for metastatic cancer with early signs of stability and consistent PK/PD data.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10 HC Wainwright & Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and lowers the price target from $20 to $10.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com TransCode Therapeutics Reports Initial Dosing In Fourth Cohort Of Phase 1 Clinical Trial With TTX-MC138 First patient in Cohort four has been treated with TTX-MC138Ten patients have been treated with TTX-MC138 at escalating dose levelsAdditional patients being evaluated for eligibility for expanded…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session